Human serum-derived hydroxy long-chain fatty acids exhibit anti-inflammatory and anti-proliferative activity. 2011

Shawn A Ritchie, and Dushmanthi Jayasinghe, and Gerald F Davies, and Pearson Ahiahonu, and Hong Ma, and Dayan B Goodenowe
Phenomenome Discoveries, Inc, Saskatoon, Saskatchewan, Canada. s.ritchie@phenomenome.com

BACKGROUND Circulating levels of novel long-chain hydroxy fatty acids (called GTAs) were recently discovered in the serum of healthy subjects which were shown to be reduced in subjects with colorectal cancer (CRC), independent of tumor burden or disease stage. The levels of GTAs were subsequently observed to exhibit an inverse association with age in the general population. The current work investigates the biological activity of these fatty acids by evaluating the effects of enriched human serum extracts on cell growth and inflammation. METHODS GTAs were extracted from commercially available bulk human serum and then chromatographically separated into enriched (GTA-positive) and depleted (GTA-negative) fractions. SW620, MCF7 and LPS stimulated RAW264.7 cells were treated with various concentrations of the GTA-positive and GTA-negative extracts, and the effects on cell growth and inflammation determined. RESULTS Enriched fractions resulted in poly-ADP ribose polymerase (PARP) cleavage, suppression of NFκB, induction of IκBα, and reduction in NOS2 mRNA transcript levels. In RAW264.7 mouse macrophage cells, incubation with enriched fractions prior to treatment with LPS blocked the induction of several pro-inflammatory markers including nitric oxide, TNFα, IL-1β, NOS2 and COX2. CONCLUSIONS Our results show that human serum extracts enriched with endogenous long-chain hydroxy fatty acids possess anti-inflammatory and anti-proliferative activity. These findings support a hypothesis that the reduction of these metabolites with age may result in a compromised ability to defend against uncontrolled cell growth and inflammation, and could therefore represent a significant risk for the development of CRC.

UI MeSH Term Description Entries
D011065 Poly(ADP-ribose) Polymerases Enzymes that catalyze the transfer of multiple ADP-RIBOSE groups from nicotinamide-adenine dinucleotide (NAD) onto protein targets, thus building up a linear or branched homopolymer of repeating ADP-ribose units i.e., POLY ADENOSINE DIPHOSPHATE RIBOSE. ADP-Ribosyltransferase (Polymerizing),Poly ADP Ribose Polymerase,Poly(ADP-Ribose) Synthase,Poly(ADP-ribose) Polymerase,PARP Polymerase,Poly ADP Ribose Transferase,Poly ADP-Ribose Synthase,Poly(ADP-Ribose) Transferase,Poly(ADPR) Polymerase,Poly(ADPribose) Polymerase,Poly ADP Ribose Synthase,Polymerase, PARP,Synthase, Poly ADP-Ribose
D005227 Fatty Acids Organic, monobasic acids derived from hydrocarbons by the equivalent of oxidation of a methyl group to an alcohol, aldehyde, and then acid. Fatty acids are saturated and unsaturated (FATTY ACIDS, UNSATURATED). (Grant & Hackh's Chemical Dictionary, 5th ed) Aliphatic Acid,Esterified Fatty Acid,Fatty Acid,Fatty Acids, Esterified,Fatty Acids, Saturated,Saturated Fatty Acid,Aliphatic Acids,Acid, Aliphatic,Acid, Esterified Fatty,Acid, Saturated Fatty,Esterified Fatty Acids,Fatty Acid, Esterified,Fatty Acid, Saturated,Saturated Fatty Acids
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D018836 Inflammation Mediators The endogenous compounds that mediate inflammation (AUTACOIDS) and related exogenous compounds including the synthetic prostaglandins (PROSTAGLANDINS, SYNTHETIC). Mediators of Inflammation,Mediators, Inflammation

Related Publications

Shawn A Ritchie, and Dushmanthi Jayasinghe, and Gerald F Davies, and Pearson Ahiahonu, and Hong Ma, and Dayan B Goodenowe
September 1994, World journal of microbiology & biotechnology,
Shawn A Ritchie, and Dushmanthi Jayasinghe, and Gerald F Davies, and Pearson Ahiahonu, and Hong Ma, and Dayan B Goodenowe
May 2010, Nutrition reviews,
Shawn A Ritchie, and Dushmanthi Jayasinghe, and Gerald F Davies, and Pearson Ahiahonu, and Hong Ma, and Dayan B Goodenowe
September 2016, Diabetes,
Shawn A Ritchie, and Dushmanthi Jayasinghe, and Gerald F Davies, and Pearson Ahiahonu, and Hong Ma, and Dayan B Goodenowe
May 1974, Journal of medical microbiology,
Shawn A Ritchie, and Dushmanthi Jayasinghe, and Gerald F Davies, and Pearson Ahiahonu, and Hong Ma, and Dayan B Goodenowe
March 1978, Biochemical pharmacology,
Shawn A Ritchie, and Dushmanthi Jayasinghe, and Gerald F Davies, and Pearson Ahiahonu, and Hong Ma, and Dayan B Goodenowe
January 1985, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
Shawn A Ritchie, and Dushmanthi Jayasinghe, and Gerald F Davies, and Pearson Ahiahonu, and Hong Ma, and Dayan B Goodenowe
June 2021, Gut,
Shawn A Ritchie, and Dushmanthi Jayasinghe, and Gerald F Davies, and Pearson Ahiahonu, and Hong Ma, and Dayan B Goodenowe
January 2002, Biological & pharmaceutical bulletin,
Shawn A Ritchie, and Dushmanthi Jayasinghe, and Gerald F Davies, and Pearson Ahiahonu, and Hong Ma, and Dayan B Goodenowe
April 2013, Applied microbiology and biotechnology,
Shawn A Ritchie, and Dushmanthi Jayasinghe, and Gerald F Davies, and Pearson Ahiahonu, and Hong Ma, and Dayan B Goodenowe
November 2019, FEMS yeast research,
Copied contents to your clipboard!